CTOs on the Move

Endo

www.endo.com

 
Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. Endo`s strategy is to centralize and unify our business, driving productivity improvements. We will focus ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.endo.com
  • 1400 Atwater Drive
    Malvern, PA USA 19355
  • Phone: 484.216.0000

Executives

Name Title Contact Details
Cheryl Stouch
 Senior Vice President, Information Technology and Chief Information Officer Profile
Mark Gaines
 Associate Director, IT Security and Infrastructure Profile

Jobs

Chief Information Security Officer

Endo Malvern, PA

Similar Companies

MRXI Corporation

MRXI Corporation is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Leiters

Leiters is a FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services. We are committed to providing healthcare professionals and their patients with high quality medications.

Hysitron

Hysitron is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.

Pharmessen Scientific

Pharmessen Scientific, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.